- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03733236
Safety and Effectiveness Evaluation of the ISS System in Treatment of Acute Ischemic Stroke (ImpACT-1)
Implant for Augmentation of Cerebral Blood Flow Trial-1. A Pilot Study Evaluating the Safety and Effectiveness of the Ischemic Stroke System for Treatment of Acute Ischemic Stroke
The primary objective of this pilot study is the assessment of the safety of the ISS500 System in patients who have experienced an acute ischemic stroke within the anterior circulation.
The secondary objectives of this study are to examine the effectiveness of the ISS500 System implantation in the treatment of acute ischemic stroke.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is an open label study in which a comparative group of patients will be prospectively selected from a resource of clinical trial data, the Virtual International Stroke Trials Archive (VISTA), on the basis of similar eligibility criteria and match for principal prognostic variables available at trial entry. Data from patients will be transferred to VISTA in a real time or at most, weekly basis and comparative group patients will be prospectively matched throughout the recruitment period. The VISTA investigators will be blinded to treatment group when receiving data from BrainsGate. The VISTA investigators will match each recruited BrainsGate patient with 3 patients from the VISTA archive. The matching criteria will include age ± 4 years; baseline NIH score matched exactly, and side of infarct.
In addition, to the end of treatment visit, in which implanted patients will undergo a device removal procedure, two follow-up visits will be performed. The visits should be performed at 30±5, and at 90±5 post enrollment. Aggregate trial duration will be ~100 days per patient, and the overall study duration will be up to 18 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Chandigarh, India
- Postgraduate Institute of Medical Education and Research
-
Hyderabad, India
- Nizam's Institute of Medical Research Punjagutta, Hyderabad.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: ≥ 18 years and ≤ 85 of both genders
- Patients with symptoms and signs of an acute ischemic hemispheric stroke within the anterior circulation.
- NIHSS ≥ 7 and ≤ 20
- Treatment can be initiated within the first 24 hours following stroke onset or since last seen normal.
- Signed informed consent has been obtained from the patient him/herself or his/her legally authorized representative
Exclusion Criteria:
- Time interval since onset of symptoms undetermined
- Treatment with ISS500 System can't start within the first 24 hours post stroke onset
- Any other imaging diagnosis including tumor, abscess, primary intracranial hemorrhage (ICH) or secondary hemorrhage (PH1-PH2) (H1 and H2 are allowed); or symptoms suspicious for sub-arachnoid hemorrhage, etc
- Clinical syndrome of an acute stroke due to lacunar infarct (pure motor hemiparesis, ataxic hemiparesis, sensorimotor stroke), unless brain imaging demonstrates a relevant lesion > 1.5 cm in size
- Not a stroke in the anterior circulation
- Minor stroke with non-disabling deficit or rapidly improving neurological symptoms with a high probably to Transient Ischemic Attack (TIA)
- Eligible to or treated with IV or IA t-PA or mechanical thrombolysis
- Baseline NIHSS >20 or < 7
- Neurological deficit that has led to stupor or coma (NIHSS level of consciousness score greater than or equal to 2)
- History of stroke in previous 6 months
- Pre-existing disability; Modified Rankin Score > 2 upon screening
- Patients under oral anticoagulants or having received heparin within 48 hours, and / or with elevated activated partial thromboplastin time (aPTT) (or INR)
- High clinical suspicion of septic embolus
- Severe cardiac disease: evidence of congestive heart failure or has history of endstage cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina)
- Uncontrolled hypertension upon enrollment (systolic >185 mmHg and/or diastolic >110 mmHg)
- Serious systemic infection
- Women known to be pregnant or having a positive or indeterminate pregnancy test
- Patients with other implanted neural stimulator
- Orthodontics or non-Hygienic condition/ problems that prevent procedures within the mouth
MRI2 contraindications, such as but not limited to:
- Central nervous system aneurysm clips
- Implanted cardiac pacemaker or defibrillator;
- Cochlear implant
- Ocular foreign body (e.g. metal shavings)
- Insulin pump
- Metal shrapnel or bullet
- Any implanted device that is incompatible with MRI.
- Patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)
- Life expectancy < 1 year from other causes
- Currently participating in any other clinical trial
- Patients unable or unwilling to follow protocol requirements
- Massive stroke, defined as acute parenchymal hypodense lesion or effacement of cerebral sulci in over a 2/3 of the MCA territory per CT (or equivalent per T2/Flair/DWI MRI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Stimulation
The Implant will be implanted using a minimal invasive approach.
Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure.
ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
|
ISS SPG stimulation and standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment successful completion
Time Frame: 5 Days
|
The need to stop the treatment sessions completely or alternately.
|
5 Days
|
Adverse Events profile at 90 Day compared to VISTA trials data
Time Frame: 90 Days
|
Adverse Events profile at 90 days post implantation will be compared to the data retrieved form the VISTA trials.
|
90 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The distribution of modified Rankin scale scores at 90 days
Time Frame: 90 Days
|
Shift in the distribution of modified Rankin Scale (mRS) scores at 90 days Favorable outcome is mRS score between 0 and 2
|
90 Days
|
NIHSS scores at 90 days
Time Frame: 90 Days
|
The distribution of total NIHSS scores at 90 days - binary NIHSS (defined as the proportion of favorable outcomes assessed using the NIHSS scale, where as favorable outcome was a complete recovery (NIHSS 0 or 1) or an improvement by 9 or more points in the NIHSS score
|
90 Days
|
Proportion of patients achieving a Barthel index at 90 days
Time Frame: 90 Days
|
The proportion of patients achieving a Barthel index of 95-100 (versus 0-90) at 90 days
|
90 Days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient and treatment compliance to the stimulation
Time Frame: 5 Days
|
The ability to maintain treatment in each session for the treatment length, and the compliance for the whole treatment period; i.e. each treatment session should be performed for at least 85% of the prescribed regimen
|
5 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Subash Kaul, Dr., Nizam's Institute of Medical Research Punjagutta, Hyderabad.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP1000450
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stricture of Intestine
-
University of Southern CaliforniaUnknownEsophageal Stricture | Duodenal Stricture | Jejunal Stricture | Anastomotic Stricture of Small IntestineUnited States
-
University College, LondonUnknownMotility Disorder of IntestineUnited Kingdom
-
University of RochesterCompletedFunctional Disorder of IntestineUnited States
-
CHU de ReimsUnknownSuspicion of Tumor of the Small IntestineFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingLiver Transplant Disorder | Biliary Stricture | Ischemic Cholangiopathy | Non-anastomotic Biliary Stricture | Biliary Stents (Plastic)Italy
-
Far Eastern Memorial HospitalUnknownRejection of an Intestine TransplantTaiwan
-
Central Hospital, Nancy, FranceNot yet recruitingStricture of Pelviureteric JunctureFrance
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIICompleted
-
Medical College of WisconsinAmerican Neurogastroenterology and Motility SocietyCompletedNausea Persistent | Functional Disorder of IntestineUnited States
-
University of FloridaCompletedBile Duct Stricture | Accuracy of Tissue Diagnosis | Pancreatic Duct StrictureUnited States
Clinical Trials on ISS Active Stimulation
-
BrainsGateCompleted
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
Raydiant Oximetry, Inc.Terminated
-
BrainsGateTerminatedAcute Ischemic StrokeSpain, Germany, United States
-
Nottingham University Hospitals NHS TrustUniversity of Nottingham; Neurotherapeutics LtdCompletedTourette Syndrome | Chronic Tic DisorderUnited Kingdom
-
Centre Hospitalier Henri LaboritMinistry of Health, FranceCompletedObsessive-Compulsive DisorderFrance
-
University Hospital, RouenMinistry of Health, FranceCompletedFecal IncontinenceFrance
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); MedtronicRecruitingParkinson Disease | Dystonia | Essential TremorUnited States
-
University of Sao PauloBrain & Behavior Research FoundationCompletedDepression, BipolarBrazil
-
Columbia UniversityUniversity of Colorado, Denver; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsRecruiting